BX20 Stock Overview A commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
BioXcel Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for BioXcel Therapeutics Historical stock prices Current Share Price US$2.56 52 Week High US$56.32 52 Week Low US$2.56 Beta -0.012 1 Month Change -56.44% 3 Month Change -73.77% 1 Year Change -92.66% 3 Year Change -98.95% 5 Year Change -99.53% Change since IPO -98.00%
Recent News & Updates
BioXcel Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Feb 07
BioXcel Therapeutics, Inc. Provides Clinical and Business Update Feb 05
BioXcel Therapeutics, Inc., Annual General Meeting, Jan 28, 2025 Dec 19 BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering. Nov 22
Bioxcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia Nov 13
BioXcel Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 08 See more updates
BioXcel Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Feb 07
BioXcel Therapeutics, Inc. Provides Clinical and Business Update Feb 05
BioXcel Therapeutics, Inc., Annual General Meeting, Jan 28, 2025 Dec 19 BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering. Nov 22
Bioxcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia Nov 13
BioXcel Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 08
BioXcel Therapeutics, Inc. and University of North Carolina at Chapel Hill Announce U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder Oct 15
BioXcel Therapeutics Receives Non-Compliance Letters from Nasdaq Regarding Minimum Bid Price Requirement Sep 22
BioXcel Therapeutics Receives Non-Compliance Letters from Nasdaq Regarding Minimum Bid Price Requirement Sep 21
BioXcel Therapeutics, Inc. Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation Sep 19
BioXcel Therapeutics, Inc. Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia Sep 05
Second quarter 2024 earnings released: US$0.21 loss per share (vs US$1.83 loss in 2Q 2023) Aug 07
BioXcel Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30 BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from Russell 3000 Index
Bioxcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating Prn Treatment of Igalmi™ (Dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia Jun 25
First quarter 2024 earnings released: US$0.87 loss per share (vs US$1.85 loss in 1Q 2023) May 10
BioXcel Therapeutics, Inc., Annual General Meeting, Jun 10, 2024 May 01
BioXcel Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 27
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential Apr 23
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia Apr 10 BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $25 million. Mar 26
BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $25 million. Mar 25
Full year 2023 earnings released: US$6.15 loss per share (vs US$5.92 loss in FY 2022) Mar 13
New major risk - Revenue and earnings growth Mar 12
BioXcel Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024 Mar 02
BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) Feb 14 BioXcel Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $60 million. Feb 13
BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $60 million. Feb 09
BioXcel Therapeutics, Inc. Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of Bxcl701 in Combination with Keytruda® Feb 07
BioXcel Therapeutics, Inc. Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine Feb 05
New minor risk - Market cap size Dec 10 BioXcel Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Nov 15
New major risk - Revenue and earnings growth Nov 15
BioXcel Therapeutics, Inc. Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype Nov 09
BioXcel Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 01
Bioxcel Therapeutics, Inc. Receives Permanent J-Code for Igalmi (Dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services Oct 31
BioXcel Therapeutics, Inc. Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (Dexmedetomidine) Sublingual Film Oct 05
BioXcel Therapeutics, Inc. Announces Board Changes Sep 26
Bioxcel Therapeutics, Inc. Receives Notice of Allowance from the U.S. Patent and Trademark Office Sep 14
Rain Oncology Inc., Proterra Inc., Bioxcel Therapeutics, Inc Announces Class Action Update Aug 17
Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023 Aug 12
BioXcel Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 01
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Bioxcel Therapeutics, Inc Jul 08
BioXcel Therapeutics Announces Positive Topline Results from TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation Jun 30
BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from Russell Small Cap Comp Value Index Jun 25
Bioxcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal Security Iii Trial of Bxcl501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia May 26
BioXcel Therapeutics, Inc., Annual General Meeting, Jun 26, 2023 May 19
BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MAD) Program May 17
No longer forecast to breakeven Mar 12
No longer forecast to breakeven Mar 10
Forecast to breakeven in 2025 Feb 25
Insufficient new directors Feb 23
Bioxcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 Asco Genitourinary Cancers Symposium Feb 14
BioXcel Therapeutics, Inc. Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer Jan 12
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease Dec 20
Insufficient new directors Dec 17
BioXcel Therapeutics, Inc. Announces First Patients Dosed in Serenity III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia Dec 01
Insufficient new directors Nov 21
BioXcel Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 28
BioXcel Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
BioXcel Therapeutics, Inc. Receives Two Notices of Allowance from the U.S. Patent and Trademark Office Jul 22
BioXcel Therapeutics, Inc. Announces That Its Product, Igalmi™ (Dexmedetomidine), A Sublingual Film for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults, Is Now Available in Doses of 120 and 180 Mcg Jul 07
BioXcel Therapeutics, Inc. Appoints Michael Miller as Class II Director and Member of Audit Committee Jul 06
BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from Russell 2000 Growth Index Jun 26
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease May 04
Insufficient new directors Apr 28 BioXcel Therapeutics, Inc. announced that it expects to receive $260 million in funding from Qatar Investment Authority, Oaktree Capital Management, L.P. Apr 20
No longer forecast to breakeven Apr 07
BioXcel Therapeutics Announces FDA Approval of IGALMI (Dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults Apr 07
BioXcel Therapeutics, Inc., Annual General Meeting, May 19, 2022 Apr 06
Insufficient new directors Apr 01
No longer forecast to breakeven Mar 13
No longer forecast to breakeven Mar 11
Insufficient new directors Mar 02
BioXcel Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Feb 25
BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders Feb 24
BioXcel Therapeutics, Inc. Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium Feb 15 Shareholder Returns BX20 DE Biotechs DE Market 7D -43.1% 1.2% 2.3% 1Y -92.7% -5.6% 16.7%
See full shareholder returns
Return vs Market: BX20 underperformed the German Market which returned 15% over the past year.
Price Volatility Is BX20's price volatile compared to industry and market? BX20 volatility BX20 Average Weekly Movement 21.2% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: BX20's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BX20's weekly volatility has increased from 16% to 21% over the past year.
About the Company BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Show more BioXcel Therapeutics, Inc. Fundamentals Summary How do BioXcel Therapeutics's earnings and revenue compare to its market cap? BX20 fundamental statistics Market cap €8.96m Earnings (TTM ) -€68.79m Revenue (TTM ) €2.21m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BX20 income statement (TTM ) Revenue US$2.28m Cost of Revenue US$2.03m Gross Profit US$251.00k Other Expenses US$71.25m Earnings -US$71.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -22.89 Gross Margin 11.03% Net Profit Margin -3,119.33% Debt/Equity Ratio -122.0%
How did BX20 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/11 14:59 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources BioXcel Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Anita Dushyanth Berenberg Guyn Kim BMO Capital Markets Equity Research Alec Stranahan BofA Global Research
Show 9 more analysts 
